29104 Federal Register / Vol. 61, No. 111 / Friday, June 7, 1996 / Notices

School Committee on Faculty Conduct,

ORI found that Eric T. Fossel, Ph.D.,

former Harvard Medical School

Associate Professor of Radiology at Beth

Israel Hospital, committed scientific

misconduct by reporting falsified

research results in a Public Health

Service (PHS) grant application.

Specifically, Dr. Fossel altered

nuclear magnetic resonance (NMR) data

in the Multicenter Breast Trial (MCBT)

such that the NMR test, purporting to

detect from a patient’s blood sample a

predisposition toward malignancy or a

relapse, appeared to be more accurate,

sensitive, and specific than was actually

the case. Premised on these falsely

reported results, Dr. Fossel proposed in

a PHS grant application that the

National Cancer Institute provide funds

to complete the MCBT.

Dr. Fossel has entered into a

Voluntary Exclusion Agreement with

ORI in which he has voluntarily agreed,

for the three (3) year period beginning

May 9, 1996, to exclude himself from:

(1) any contracting or subcontracting

with any agency of the United States

Government and from eligibility for, or

involvement in, nonprocurement

transactions (e.g., grants and cooperative

agreements) of the United States

Government as defined in 45 CFR Part

76 (Debarment Regulations), and

(2) serving in any advisory capacity to

PHS, including but not limited to

service on any PHS advisory committee,

board, and/or peer review committee, or

as a consultant.

No scientific publications were

required to be corrected as part of this

Agreement.

FOR FURTHER INFORMATION CONTACT:

Director, Division of Research

Investigations, Office of Research

Integrity, 5515 Security Lane, Suite 700,

Rockville, MD 20852.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 96–14389 Filed 6–6–96; 8:45 am]

BILLING CODE 4160–17–P

Centers for Disease Control and

Prevention

Disease, Disability, and Injury

Prevention and Control Special

Emphasis Panel (SEP): Teleconference

Meetings

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meetings.

Name: Disease, Disability, and Injury

Prevention and Control SEP: Cooperative

Agreements for Prevention Centers/National

Center for Chronic Disease Prevention and

Health Promotion—General Special Interest

Projects, Panel Number 1, Program

Announcements 328, 432, and 461.

Time and Date: 1 p.m.-5 p.m., June 24,

1996.

Place: National Center for Chronic Disease

Prevention and Health Promotion

(NCCDPHP), CDC, Rhodes Building, Koger

Office Park, 3005 Chamblee-Tucker Road,

Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Discussed: The meeting will

include the review, discussion, and

evaluation of applications received in

response to Program Announcements 328,

432, and 461 entitled, ‘‘Cooperative

Agreements for Prevention Centers/

NCCDPHP—General Special Interest

Projects.’’

Contact Person for More Information:

James E. Barrow, Deputy Director, Division of

Adult and Community Health, NCCDPHP,

CDC, 4770 Buford Highway, NE, M/S K30,

Chamblee, Georgia 30341, telephone 770/

488–5269.

Name: Disease, Disability, and Injury

Prevention and Control SEP: Cooperative

Agreements for Prevention Centers Program/

NCCDPHP—General Special Interest Projects,

Panel Number 2, Program Announcements

328, 432, and 461.

Time and Date: 1 p.m.–5 p.m., June 25,

1996.

Place: NCCDPHP, CDC, Rhodes Building,

Koger Office Park, 3005 Chamblee-Tucker

Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Discussed: The meeting will

include the review, discussion, and

evaluation of applications received in

response to Program Announcements 328,

432, and 461 entitled, ‘‘Cooperative

Agreements for Prevention Centers/

NCCDPHP—General Special Interest

Projects.’’

Contact Person for More Information:

Michael N. Waller, Program Manager,

Division of Adult and Community Health,

NCCDPHP, CDC, 4770 Buford Highway, NE,

M/S K30, Chamblee, Georgia 30341,

telephone 770/488–5292.

Name: Disease, Disability, and Injury

Prevention and Control SEP: Cooperative

Agreements for Prevention Centers Program/

NCCDPHP—General Special Interest Projects,

Panel Number 3, Program Announcements

328, 432, and 461.

Time and Date: 1 p.m.–5 p.m., June 26,

1996.

Place: NCCDPHP, CDC, Rhodes Building,

Koger Office Park, 3005 Chamblee-Tucker

Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Considered: The meeting

will include the review, discussion, and

evaluation of applications received in

response to Program Announcements 328,

432, and 461 entitled, ‘‘Cooperative

Agreements for Prevention Centers/

NCCDPHP—General Special Interest

Projects.’’

Contact Person for More Information: Craig

L. Leutzinger, Public Health Advisor,

Division of Adult and Community Health,

NCCDPHP, CDC, 4770 Buford Highway, NE,

M/S K30, Chamblee, Georgia 30341,

telephone 770/488–5304.

These meetings will be closed to the public

in accordance with provisions set forth in

section 552b(c) (4) and (6), title 5 U.S.C., and

the Determination of the Associate Director

for Management and Operations, CDC,

pursuant to Pub. L. 92–463.

Dated: May 31, 1996.

John C. Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–14381 Filed 6–6–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Advisory Committee Meeting;

Cancellation

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is cancelling the

meeting of the Science Board to the

Food and Drug Administration

scheduled for June 13, 1996, to provide

time for the agency to continue its

development of strategies to address

toxicity, carcinogenicity, and

biomaterials testing. The meeting was

announced in the Federal Register of

May 24, 1996 (61 FR 26187).

FOR FURTHER INFORMATION CONTACT:

Susan A. Homire, Office of Science

(HF–33), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–3340; or

call the FDA Advisory Committee

Information Hotline, 1–800–741–8138

(301–443–0572) in the Washington, DC

area, Science Board to the Food and

Drug Administration, code 12603.

Dated: June 3, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–14388 Filed 6–06–96; 8:45 am]

BILLING CODE 4160–01–F

Memorandum of Understanding

Between the Food and Drug

Administration and the U.S.

Department of Agriculture and the

Russian Federation

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is providing

notice of a memorandum of

understanding (MOU) between FDA and

the U.S. Department of Agriculture and